Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.75
ALIM's Cash-to-Debt is ranked lower than
63% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ALIM: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
ALIM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 3.55 Max: 6017.9
Current: 0.75
0.32
6017.9
Equity-to-Asset 0.32
ALIM's Equity-to-Asset is ranked lower than
87% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ALIM: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
ALIM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.32 Max: 0.46
Current: 0.32
-0.25
0.46
Debt-to-Equity 1.66
ALIM's Debt-to-Equity is ranked lower than
93% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. ALIM: 1.66 )
Ranked among companies with meaningful Debt-to-Equity only.
ALIM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.99  Med: 0.32 Max: 4.13
Current: 1.66
-0.99
4.13
Debt-to-EBITDA -2.58
ALIM's Debt-to-EBITDA is ranked lower than
99.99% of the 511 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ALIM: -2.58 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALIM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.58  Med: -0.29 Max: 0
Current: -2.58
-2.58
0
Piotroski F-Score: 3
Altman Z-Score: -6.81
Beneish M-Score: -3.00
WACC vs ROIC
17.28%
-56.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -42.94
ALIM's Operating Margin % is ranked lower than
83% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.71 vs. ALIM: -42.94 )
Ranked among companies with meaningful Operating Margin % only.
ALIM' s Operating Margin % Range Over the Past 10 Years
Min: -1837.82  Med: -282.49 Max: -42.94
Current: -42.94
-1837.82
-42.94
Net Margin % -55.29
ALIM's Net Margin % is ranked lower than
83% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. ALIM: -55.29 )
Ranked among companies with meaningful Net Margin % only.
ALIM' s Net Margin % Range Over the Past 10 Years
Min: -2469.5  Med: -281.46 Max: -55.29
Current: -55.29
-2469.5
-55.29
ROE % -87.61
ALIM's ROE % is ranked lower than
91% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. ALIM: -87.61 )
Ranked among companies with meaningful ROE % only.
ALIM' s ROE % Range Over the Past 10 Years
Min: -299.13  Med: -104.32 Max: -61.59
Current: -87.61
-299.13
-61.59
ROA % -30.59
ALIM's ROA % is ranked lower than
83% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. ALIM: -30.59 )
Ranked among companies with meaningful ROA % only.
ALIM' s ROA % Range Over the Past 10 Years
Min: -329.68  Med: -48.29 Max: -20.46
Current: -30.59
-329.68
-20.46
ROC (Joel Greenblatt) % -159.80
ALIM's ROC (Joel Greenblatt) % is ranked lower than
83% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.46 vs. ALIM: -159.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALIM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12190.35  Med: -3400.49 Max: -159.8
Current: -159.8
-12190.35
-159.8
3-Year Revenue Growth Rate 122.50
ALIM's 3-Year Revenue Growth Rate is ranked higher than
99% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALIM: 122.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALIM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 122.5
Current: 122.5
0
122.5
3-Year EBITDA Growth Rate -24.10
ALIM's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. ALIM: -24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALIM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.6 Max: 5.6
Current: -24.1
0
5.6
3-Year EPS without NRI Growth Rate -27.00
ALIM's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. ALIM: -27.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALIM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.35 Max: 19.6
Current: -27
0
19.6
GuruFocus has detected 2 Warning Signs with Alimera Sciences Inc ALIM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALIM's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ALIM Guru Trades in Q1 2017

Jim Simons Sold Out
» More
Q2 2017

ALIM Guru Trades in Q2 2017

Jim Simons 66,900 sh (New)
» More
Q3 2017

ALIM Guru Trades in Q3 2017

Jim Simons 468,005 sh (+599.56%)
» More
Q4 2017

ALIM Guru Trades in Q4 2017

Jim Simons 416,400 sh (-11.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Alimera Sciences Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:ORSE:GRD1R, XKRX:014570, TSE:4512, OSTO:OASM, ROCO:8432, HKSE:00455, KAR:FEROZ, BOM:531633, UKEX:FARM, BSE:ATB, LSE:EAST, OSL:PHO, ROCO:4166, XKRX:118000, TSE:4586, ASX:OPT, ASX:PXS, BOM:507747, NSA:GLAXOSMITH, XLJU:SALR » details
Traded in other countries:ASZ.Germany,
Headquarter Location:USA
Alimera Sciences Inc is a biopharmaceutical company which is engaged in the research, development, and commercialization of ophthalmic pharmaceuticals.

Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.

Ratios

vs
industry
vs
history
PS Ratio 2.26
ALIM's PS Ratio is ranked higher than
65% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ALIM: 2.26 )
Ranked among companies with meaningful PS Ratio only.
ALIM' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 7.05 Max: 853.33
Current: 2.26
1.64
853.33
EV-to-EBIT -10.34
ALIM's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.21 vs. ALIM: -10.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIM' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.8  Med: -6.9 Max: -2
Current: -10.34
-10.8
-2
EV-to-EBITDA -12.43
ALIM's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. ALIM: -12.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALIM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13  Med: -7.5 Max: -2
Current: -12.43
-13
-2
EV-to-Revenue 4.44
ALIM's EV-to-Revenue is ranked lower than
59% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ALIM: 4.44 )
Ranked among companies with meaningful EV-to-Revenue only.
ALIM' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.1  Med: 10.5 Max: 931.8
Current: 4.44
4.1
931.8
Current Ratio 4.84
ALIM's Current Ratio is ranked higher than
75% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. ALIM: 4.84 )
Ranked among companies with meaningful Current Ratio only.
ALIM' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.2 Max: 11.78
Current: 4.84
0.59
11.78
Quick Ratio 4.65
ALIM's Quick Ratio is ranked higher than
79% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. ALIM: 4.65 )
Ranked among companies with meaningful Quick Ratio only.
ALIM' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.15 Max: 11.78
Current: 4.65
0.59
11.78
Days Inventory 110.90
ALIM's Days Inventory is ranked higher than
54% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.37 vs. ALIM: 110.90 )
Ranked among companies with meaningful Days Inventory only.
ALIM' s Days Inventory Range Over the Past 10 Years
Min: 110.9  Med: 292.87 Max: 445.49
Current: 110.9
110.9
445.49
Days Sales Outstanding 131.14
ALIM's Days Sales Outstanding is ranked lower than
79% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.67 vs. ALIM: 131.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALIM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.83  Med: 122.31 Max: 159.4
Current: 131.14
36.83
159.4
Days Payable 583.19
ALIM's Days Payable is ranked higher than
97% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.56 vs. ALIM: 583.19 )
Ranked among companies with meaningful Days Payable only.
ALIM' s Days Payable Range Over the Past 10 Years
Min: 339.92  Med: 802.71 Max: 1270.92
Current: 583.19
339.92
1270.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.10
ALIM's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.00 vs. ALIM: -27.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -175  Med: -6.25 Max: 0
Current: -27.1
-175
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.31
ALIM's Price-to-Median-PS-Value is ranked higher than
97% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. ALIM: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALIM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.39 Max: 122
Current: 0.31
0.23
122
Earnings Yield (Greenblatt) % -9.67
ALIM's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 868 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.18 vs. ALIM: -9.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALIM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49.3  Med: -14.5 Max: -9.2
Current: -9.67
-49.3
-9.2

More Statistics

Revenue (TTM) (Mil) $37.45
EPS (TTM) $ -0.29
Beta2.49
Short Percentage of Float1.63%
52-Week Range $1.03 - 1.72
Shares Outstanding (Mil)69.15

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 39 48
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.24 -0.10
EPS without NRI ($) -0.24 -0.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}